Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capromorelin
- Development stage
- Phase 1
- Lead developer
- Aratana Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Capromorelin is an orally active small-molecule ghrelin receptor agonist used primarily as a veterinary medication to stimulate appetite and manage weight loss in dogs and cats. It mimics the action of endogenous ghrelin by binding to the growth hormone secretagogue receptor 1a (GHS-R1a) in the pituitary gland, leading to increased secretion of growth hormone and insulin-like growth factor-1 (IGF-1). This results in enhanced appetite via hypothalamic pathways and may also increase lean muscle mass over time. Capromorelin is marketed under the brand names Entyce (for dogs) and Elura (for cats), with FDA approval for use as an appetite stimulant in these species. Human studies were discontinued after initial trials[4][7][8]. Developers: Aratana Therapeutics Manufacturers: Elanco
- Brand names
- EntyceElura
- Other names
- capromorelin tartrate
02
Targets
GHSR (Growth hormone secretagogue receptor)
Beyond the preview
Go deeper on capromorelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capromorelin.